{"name":"Akili Interactive","slug":"akili","ticker":"AKLI","exchange":"NASDAQ (Delisted)","domain":"akiliinteractive.com","description":"Akili Interactive is a digital therapeutics company focused on developing treatments for attention deficit hyperactivity disorder (ADHD) and other cognitive disorders. The company's top product is EndeavorRx, a prescription video game approved by the FDA for the treatment of ADHD in children. Akili Interactive has a strong market position in the digital therapeutics space, with a growing pipeline of products in development.","hq":"Boston, MA","founded":0,"employees":"","ceo":"Eddie Martucci (Founder)","sector":"Digital Therapeutics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$34M (acquisition price)","metrics":{"revenue":4500000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2022-06-30","type":"earnings","headline":"Akili Interactive Reports Q2 2022 Financial Results","summary":"Akili Interactive reported revenue of $4.3 million for the second quarter of 2022, a 25% increase from the same period in 2021.","drugName":"","sentiment":"neutral"},{"date":"2021-11-18","type":"regulatory","headline":"FDA Approves EndeavorRx for Treatment of ADHD in Children","summary":"The FDA approved EndeavorRx, a prescription video game developed by Akili Interactive, for the treatment of attention deficit hyperactivity disorder (ADHD) in children aged 8-12.","drugName":"","sentiment":"positive"},{"date":"2020-12-14","type":"deal","headline":"Akili Interactive Partners with Pfizer to Develop Digital Therapeutics for ADHD","summary":"Akili Interactive partnered with Pfizer to develop digital therapeutics for attention deficit hyperactivity disorder (ADHD) in children and adolescents.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQVXZRcGN2U3BpalBHYlZUaVFzYlhNRmtIbFNXZWxpNXRqYmRTY1llYzk5ZlhveVJRa2l5MUZzc1B2UWZLOGQzWHg4bnNmU3hTU2J1cDMyTVJUTWxHN3FjWTFmZDVDVWZqdy1MeU95U0dfQWNPMm5IV0hRMTBvT2N4b0hEandMY3ZYWlpkX0hDQjRHUGRSaUU4X2dQRXNHd20waHJCNERzX0lPckc3WnF0T1J4RQ?oc=5","date":"2024-05-30","type":"pipeline","source":"Fierce Biotech","summary":"ADHD game developer Akili Interactive to be taken private, after $34M sale - Fierce Biotech","headline":"ADHD game developer Akili Interactive to be taken private, after $34M sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9nTzFoRXE4YktMcG84eVdSRXhRZUxRQXE2YkY1eWhva1Rmbl9FUDFQd1Z1RXdRUzNnVmktRDM1Q1hFd2ZnTWxHZldlNU1tNGpqN1hRcHZOX2lGYkp0RmVkNVExSlhkbnRSc28yX0lNdFgzVG1KUnF3T1JRUQ?oc=5","date":"2024-02-26","type":"pipeline","source":"InvestorPlace","summary":"Why Is Akili (AKLI) Stock Up 110% Today? - InvestorPlace","headline":"Why Is Akili (AKLI) Stock Up 110% Today?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPLXRmY21YQ3FoWTVpSjRMRjhObnA3STZBUzZOQUJQYWR4aTZfeF8xMHRiUjhTc1hMd1dwanlfRHIzTU5lOTFDdGxNbXRhcUNGendvdTlDdEgxdXJLbGRmZnNmTDdNUXpYOFFhMkVTcl90eVBwMGNGR2V3RktyXzJad0t3eFBsSk5Id0Y0NHU4ejZrSE1kdVN2aEpFalpNWHg0RFVlWXEwVHY?oc=5","date":"2022-01-26","type":"deal","source":"Fierce Biotech","summary":"Akili inks $1B SPAC deal to take prescription video game tech public - Fierce Biotech","headline":"Akili inks $1B SPAC deal to take prescription video game tech public","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Mindstrong Health","Click Therapeutics","Pear Therapeutics"],"therapeuticFocus":["Attention Deficit Hyperactivity Disorder (ADHD)","Cognitive Disorders"],"financials":null,"yahoo":null}